Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

C. Tarella, M. Zanni, M. Di Nicola, C. Patti, R. Calvi, A. Pescarollo, V. Zoli, A. Fornari, D. Novero, A. Cabras, M. Stella, A. Comino, D. Remotti, M. Ponzoni, D. Caracciolo, M. Ladetto, M. Magni, L. Devizzi, R. Rosato, M. BoccadoroM. Bregni, P. Corradini, A. Gallamini, I. Majolino, S. Mirto, A. M. Gianni

Research output: Contribution to journalArticle


A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged

Original languageEnglish
Pages (from-to)1802-1811
Number of pages10
Issue number8
Publication statusPublished - Aug 2007


ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this